Amakem N.V. is using its localized drug action technology to reduce the side effects of treatments for ophthalmic diseases. The company hopes to establish proof of principle for the technology with a Rho kinase inhibitor for glaucoma.

Amakem acquired the technology and therapeutics from Devgen N.V. after the latter decided to exit the pharmaceutical space and focus on agricultural biotechnology.